Trial Profile

A Phase I, Multi-center, Open-label Study to Investigate the Pharmacokinetic Interactions of RO5185416 with a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients with Previously Treated and Untreated Metastatic Melanoma.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vemurafenib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Vitamin K; Warfarin
Indications Malignant melanoma
Focus Pharmacokinetics
Sponsors Roche

03 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
23 May 2013 Planned end date changed from 1 Oct 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
05 Jul 2012 Actual patient number changed from 16 to 22 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com